Treatment of advanced breast cancer in elderly women

Medical approach

A. Brunello, A. Jirillo, C. Falci, S. Lonardi, U. Basso, Silvio Monfardini

Research output: Contribution to journalArticle

Abstract

Breast cancer is the most common malignancy in women worldwide, and represents the leading cause of death in the female population. Incidence of breast cancer increases with age, and older patients are more likely to have disseminated disease at diagnosis. The majority of breast cancer in older women is hormone-receptor positive, therefore, endocrine treatment with tamoxifen or aromatase inhibitors must be considered as first choice. For those patients who relapse after endocrine treatment or in whom the tumor does not express hormone receptors, chemotherapy should be considered. Single-agent sequential regimens should be preferred to combination regimens, which are usually more toxic and provide a limited survival gain. Trastuzumab in association with chemotherapy can be administered to elderly patients who present with HER2-overexpressing tumors, although cardiac monitoring is necessary owing to cardiac adverse events. Some geriatric assessment tools could help in qualifying those patients who can be treated with conventional therapy from those who should receive adjusted regimens, and from those who are frail and should be managed with the best supportive care.

Original languageEnglish
Pages (from-to)267-277
Number of pages11
JournalAging Health
Volume4
Issue number3
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Breast Neoplasms
Hormones
Geriatric Assessment
Drug Therapy
Aromatase Inhibitors
Heart Neoplasms
Poisons
Tamoxifen
Therapeutics
Cause of Death
Neoplasms
Recurrence
Survival
Incidence
Population
Trastuzumab

Keywords

  • Breast cancer
  • Chemotherapy
  • Elderly
  • Endocrine therapy

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Treatment of advanced breast cancer in elderly women : Medical approach. / Brunello, A.; Jirillo, A.; Falci, C.; Lonardi, S.; Basso, U.; Monfardini, Silvio.

In: Aging Health, Vol. 4, No. 3, 06.2008, p. 267-277.

Research output: Contribution to journalArticle

@article{fdd33053897b420c96ceb4e2105351d9,
title = "Treatment of advanced breast cancer in elderly women: Medical approach",
abstract = "Breast cancer is the most common malignancy in women worldwide, and represents the leading cause of death in the female population. Incidence of breast cancer increases with age, and older patients are more likely to have disseminated disease at diagnosis. The majority of breast cancer in older women is hormone-receptor positive, therefore, endocrine treatment with tamoxifen or aromatase inhibitors must be considered as first choice. For those patients who relapse after endocrine treatment or in whom the tumor does not express hormone receptors, chemotherapy should be considered. Single-agent sequential regimens should be preferred to combination regimens, which are usually more toxic and provide a limited survival gain. Trastuzumab in association with chemotherapy can be administered to elderly patients who present with HER2-overexpressing tumors, although cardiac monitoring is necessary owing to cardiac adverse events. Some geriatric assessment tools could help in qualifying those patients who can be treated with conventional therapy from those who should receive adjusted regimens, and from those who are frail and should be managed with the best supportive care.",
keywords = "Breast cancer, Chemotherapy, Elderly, Endocrine therapy",
author = "A. Brunello and A. Jirillo and C. Falci and S. Lonardi and U. Basso and Silvio Monfardini",
year = "2008",
month = "6",
doi = "10.2217/1745509X.4.3.267",
language = "English",
volume = "4",
pages = "267--277",
journal = "Aging Health",
issn = "1745-509X",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Treatment of advanced breast cancer in elderly women

T2 - Medical approach

AU - Brunello, A.

AU - Jirillo, A.

AU - Falci, C.

AU - Lonardi, S.

AU - Basso, U.

AU - Monfardini, Silvio

PY - 2008/6

Y1 - 2008/6

N2 - Breast cancer is the most common malignancy in women worldwide, and represents the leading cause of death in the female population. Incidence of breast cancer increases with age, and older patients are more likely to have disseminated disease at diagnosis. The majority of breast cancer in older women is hormone-receptor positive, therefore, endocrine treatment with tamoxifen or aromatase inhibitors must be considered as first choice. For those patients who relapse after endocrine treatment or in whom the tumor does not express hormone receptors, chemotherapy should be considered. Single-agent sequential regimens should be preferred to combination regimens, which are usually more toxic and provide a limited survival gain. Trastuzumab in association with chemotherapy can be administered to elderly patients who present with HER2-overexpressing tumors, although cardiac monitoring is necessary owing to cardiac adverse events. Some geriatric assessment tools could help in qualifying those patients who can be treated with conventional therapy from those who should receive adjusted regimens, and from those who are frail and should be managed with the best supportive care.

AB - Breast cancer is the most common malignancy in women worldwide, and represents the leading cause of death in the female population. Incidence of breast cancer increases with age, and older patients are more likely to have disseminated disease at diagnosis. The majority of breast cancer in older women is hormone-receptor positive, therefore, endocrine treatment with tamoxifen or aromatase inhibitors must be considered as first choice. For those patients who relapse after endocrine treatment or in whom the tumor does not express hormone receptors, chemotherapy should be considered. Single-agent sequential regimens should be preferred to combination regimens, which are usually more toxic and provide a limited survival gain. Trastuzumab in association with chemotherapy can be administered to elderly patients who present with HER2-overexpressing tumors, although cardiac monitoring is necessary owing to cardiac adverse events. Some geriatric assessment tools could help in qualifying those patients who can be treated with conventional therapy from those who should receive adjusted regimens, and from those who are frail and should be managed with the best supportive care.

KW - Breast cancer

KW - Chemotherapy

KW - Elderly

KW - Endocrine therapy

UR - http://www.scopus.com/inward/record.url?scp=48249150024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249150024&partnerID=8YFLogxK

U2 - 10.2217/1745509X.4.3.267

DO - 10.2217/1745509X.4.3.267

M3 - Article

VL - 4

SP - 267

EP - 277

JO - Aging Health

JF - Aging Health

SN - 1745-509X

IS - 3

ER -